Why is Orchid Pharma falling/rising?

As of 25-Aug, Orchid Pharma Ltd's stock price is currently at Rs 791.45, reflecting an increase of Rs 19.45 or 2.52%. The stock has outperformed its sector today by 2.11%, reaching an intraday high of Rs 801.3, which is a 3.8% increase. Over the past week, the stock has shown a return of +5.12%, and +10.88% over the past month, indicating a positive short-term trend. However, the company has faced significant challenges, including a weak long-term fundamental strength with an average Return on Equity (ROE) of 4.68% and a concerning decline in operating profit of -19.64%. Additionally, the company has reported negative results for the last three consecutive quarters, which has contributed to a substantial year-to-date decline of -56.45% and a one-year return of -42.78%.
In the broader market context, while the Sensex has shown a modest gain of +0.45% over the past week and +0.21% over the past month, Orchid Pharma's recent performance has been significantly better in the short term. However, the stock's long-term performance remains troubling, with a stark underperformance compared to the market, as evidenced by its -42.78% return over the last year against the benchmark's -2.11%. The high institutional holdings at 20.82% suggest that more informed investors are involved, but the company's weak financial metrics, including a poor EBIT to Interest ratio and declining profits, raise concerns about its sustainability and future growth, which could impact investor sentiment moving forward.